Literature DB >> 15736403

Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice.

Tadashi Ohara1, Tetsuo Morishita, Hidekazu Suzuki, Tatsuhiro Masaoka, Hiromasa Ishii, Toshifumi Hibi.   

Abstract

BACKGROUND: The effects of bacterial eradication therapy cannot be fully explained simply by elimination of the target bacteria, if one considers the effects of eradication therapy in H. pylori-negative cases of low-grade malignancy MALTomas of the rectum. The present study was undertaken to examine the possibility and mechanism of direct induction of apoptosis of the tumor cells by the antibiotics used for bacterial eradication therapy.
MATERIALS AND METHODS: A B cell lymphoma cell line (300-19) derived from BALB/c mice was co-cultured with amoxicillin or clarithromycin, and amoxicillin and clarithromycin at concentrations equal to or 1/10 x MIC of either drug. Cells co-cultured with 1/100 x MIC of the standard anti-tumor agents, adriamycin, vincristine and cyclophosphamide, served as positive controls. Cells cultured without any antibiotic or anti-tumor agent served as controls. In each group, the following analyses were performed: (i) the time-course of changes in the cellular morphology, (ii) the time-course of occurrence of DNA fragmentation, (iii) the appearance of apoptotic changes as evaluated by trypan blue staining, (iv) Bcl-2 expression as examined by immunoblotting; and (v) the expression of TNFR1, Fas, FasL and caspase-3, -8 and -9, as evaluated by immunoblotting.
RESULTS: Cells treated with amoxicillin and clarithromycin showed the formation of apoptotic bodies, and degeneration and detachment of the cells in a dose-dependent manner. DNA fragmentation was induced in these cells to a degree similar to that seen in cells treated with the anti-tumor agents. Trypan blue staining also demonstrated apoptosis of the cells and loss of cell viability. Bcl-2 expression was seen only in the control group and FasL was never seen, while the expression of TNFR1, Fas and caspase-3, -8 and -9 was seen in the amoxicillin-treated group, clarithromycin-treated group, amoxicillin and clarithromycin-treated group and the positive control group.
CONCLUSION: Antibiotics used for the eradication of H. pylori can also directly induce apoptosis in mouse B cell lymphoma cells, an action which involves the TNF system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15736403

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.

Authors:  Francesca Gay; S Vincent Rajkumar; Morton Coleman; Shaji Kumar; Tomer Mark; Angela Dispenzieri; Roger Pearse; Morie A Gertz; John Leonard; Martha Q Lacy; Selina Chen-Kiang; Vivek Roy; David S Jayabalan; John A Lust; Thomas E Witzig; Rafael Fonseca; Robert A Kyle; Philip R Greipp; A Keith Stewart; Ruben Niesvizky
Journal:  Am J Hematol       Date:  2010-09       Impact factor: 10.047

2.  A case of follicular B-cell lymphoma treated using clarithromycin.

Authors:  Masashi Ohe; Satoshi Hashino
Journal:  Korean J Hematol       Date:  2011-09-30

3.  Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.

Authors:  Nagwa I Abdel-Hamid; Mona F El-Azab; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-09       Impact factor: 3.000

4.  Treatment of newly diagnosed multiple myeloma.

Authors:  Antonio Palumbo; Valeria Magarotto; Alessandra Larocca; Sara Bringhen; Patrizia Falco; Francesco Di Raimondo; Luca Baldini; Mario Boccadoro
Journal:  Curr Hematol Malig Rep       Date:  2008-04       Impact factor: 3.952

5.  Successful treatment of recurrent follicular B-cell lymphoma with clarithromycin, prednisolone, and cyclophosphamide.

Authors:  Masashi Ohe; Satoshi Hashino
Journal:  Korean J Intern Med       Date:  2013-05-01       Impact factor: 2.884

Review 6.  Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2008-11-19

7.  Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.

Authors:  Noemi Puig; Miguel T Hernández; Laura Rosiñol; Esther González; Felipe de Arriba; Albert Oriol; Verónica González-Calle; Fernando Escalante; Javier de la Rubia; Mercedes Gironella; Rafael Ríos; Ricarda García-Sánchez; José M Arguiñano; Adrián Alegre; Jesús Martín; Norma C Gutiérrez; María J Calasanz; María L Martín; María Del Carmen Couto; María Casanova; Mario Arnao; Ernesto Pérez-Persona; Sebastián Garzón; Marta S González; Guillermo Martín-Sánchez; Enrique M Ocio; Morton Coleman; Cristina Encinas; Ana M Vale; Ana I Teruel; María Cortés-Rodríguez; Bruno Paiva; M Teresa Cedena; Jesús F San-Miguel; Juan J Lahuerta; Joan Bladé; Ruben Niesvizky; María-Victoria Mateos
Journal:  Blood Cancer J       Date:  2021-05-21       Impact factor: 11.037

8.  Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.

Authors:  Shota Moriya; Xiao-Fang Che; Seiichiro Komatsu; Akihisa Abe; Tomohiro Kawaguchi; Akihiko Gotoh; Masato Inazu; Akio Tomoda; Keisuke Miyazawa
Journal:  Int J Oncol       Date:  2013-03-28       Impact factor: 5.650

9.  Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.

Authors:  Seiichiro Komatsu; Keisuke Miyazawa; Shota Moriya; Akiko Takase; Munekazu Naito; Masato Inazu; Norio Kohno; Masahiro Itoh; Akio Tomoda
Journal:  Int J Oncol       Date:  2011-12-23       Impact factor: 5.650

10.  Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone.

Authors:  Masashi Ohe; Satoshi Hashino; Atsuo Hattori
Journal:  Korean J Hematol       Date:  2012-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.